Skip to content

Percutaneous radiofrequency ablation of small breast cancer

Percutaneous radiofrequency ablation of small breast cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029665
Enrollment
Unknown
Registered
2020-02-09
Start date
2020-02-17
Completion date
Unknown
Last updated
2020-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Single arm:Radiofrequency ablation

Sponsors

The First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Female, older than 18 years; 2. Pathological diagnosis of breast cancer by thick needle puncture without distant metastasis; 3. B-ultrasound or molybdenum target confirmed as a single breast neoplasm with no suspected dispersed intraductal cancer components; 4. The diameter of the tumor measured by B-ultrasound in the supine position less than 3 cm. The distance of the tumor from chest wall, nipple and skin more than 0.5 cm; 5. Karnofsky score >= 70%; 6. Informed consent.

Exclusion criteria

Exclusion criteria: 1. Evidence of extensive intraductal carcinogenesis in invasive breast cancer; 2. Multifocal breast tumors; 3. Duration of pregnancy or lactation; 4. Patients with coagulative disease, chronic liver disease or renal failure; 5. HIV infection or the presence of AIDS-related diseases, or severe acute and chronic diseases; 6. Severe active infections (>grade 2, NCI-CTCAE 3.0); 7. People with low compliance assessed by researchers; 8. Epilepsy patients requiring medication (e.g. steroids or antiepileptic drugs); 9. Psychological or psychiatric disorders such as drug abuse or the possibility that patients may interfere with research compliance; 10. Receiving systemic chemotherapy, targeted drug therapy or local radiotherapy; 11. Any situation that is unstable or may endanger the safety and compliance of patients in this study.

Design outcomes

Primary

MeasureTime frame
Complete ablation rate;

Secondary

MeasureTime frame
Disease-freesurvival, DFS;Overallsurvival, OS;T cell;NK cell;Immune cells;

Countries

China

Contacts

Public ContactWang Shui

The First Affiliated Hospital of Nanjing Medical University

ws0801@hotmail.com+86 13701458115

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026